Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial. — CFSMEATLAS
Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial.
Sulheim, Dag, Fagermoen, Even, Winger, Anette et al. · JAMA pediatrics · 2014 · DOI
Quick Summary
This study looked at whether adolescents with ME/CFS have overactive stress response systems in their bodies and whether a medication called clonidine could help. Researchers found that young people with ME/CFS did have higher levels of stress chemicals and signs of body inflammation compared to healthy teens, but the medication did not improve their condition and actually reduced their physical activity. The study suggests that the overactive stress response may be the body's attempt to cope with ME/CFS rather than the root cause.
Why It Matters
This study provides objective evidence of specific biological abnormalities in adolescent ME/CFS—sympathetic hyperactivity, inflammation, and HPA axis dysfunction—validating a physiological basis for the condition. The unexpected finding that sympathetic inhibition worsens activity suggests current treatment approaches targeting these pathways may be counterproductive and informs future therapeutic strategies.
Observed Findings
CFS patients showed significantly lower daily step counts, lower urinary cortisol/creatinine ratio, higher plasma norepinephrine levels, higher heart rate responsiveness, higher fatigue scores, and elevated serum C-reactive protein compared to healthy controls at baseline.
Clonidine treatment reduced plasma norepinephrine (mean difference −42 pg/mL, P=.01) and serum CRP (ratio 0.69, P=.02) compared to placebo.
Clonidine treatment was associated with further reduction in daily steps (−637 steps, P=.07) compared to placebo.
No significant differences in blood microbiology between CFS patients and controls.
Inferred Conclusions
Adolescent ME/CFS is characterized by enhanced sympathetic activity, low-grade systemic inflammation, HPA axis hypofunction, cognitive impairment, and severe activity reduction, but not by chronic infection with common microorganisms.
Sympatho-inhibition by clonidine successfully reduced sympathetic outflow and inflammatory markers but paradoxically decreased physical activity, suggesting sympathetic activation may represent a compensatory mechanism supporting activity maintenance.
Low-dose clonidine is not clinically useful in treating adolescent ME/CFS.
Remaining Questions
Why does reduction of sympathetic activity through clonidine paradoxically worsen physical activity, and what compensatory mechanisms are being disrupted?
What This Study Does Not Prove
The study does not prove that sympathetic hyperactivity causes ME/CFS; these abnormalities may be secondary responses to an underlying pathology. A single failed pharmacological trial does not rule out the involvement of the sympathetic nervous system in disease pathogenesis. The findings are limited to adolescents and may not generalize to adult populations.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →